April 2021 Volume 17, Issue 4
Volume 17, Issue 4 | April 2021
April 2021
In this Issue
Clinical Trials
Clinical trial transformation
Decentralization accelerates during pandemic, with positive results
JSP191 data positive for cell transplantation
The anti-CD117 antibody is being evaluated as a conditioning agent prior to blood stem cell transplantationGo with your gut (microbiome)
Study details results on a new method for treating immunotherapy-resistant melanoma patientsTools & Technology
New support for customized exosomes
Ciloa’s therapeutic protein platform recognized by Sanofi award programAssembling the kit against COVID-19
Highlights of some of the most recent new R&D tools to curb the pandemicNew promise for drugs against difficult targets
Salipro awarded European patent for direct extraction of membrane proteins and library generationDiagnostics
Grading non-alcoholic steatohepatitis
Median Technologies teams up with UC San Diego on diagnosing liver fibrosis severity in NASH patients
Brain biomarkers for depression and trauma
Combining machine learning and EEG may have identified an imaging biomarker for better treating PTSD and MDD
Reducing the risk of bacteremia
New biomarkers can predict risk of patients dying from bacteremia
Liquid biopsy for the win in cancer
Twist Bioscience launches NGS methylation detection system for cancer analysis and epigenetic studiesDiscovery
Bacteria vs. bacteria
A multi-organization academic team reports on their efforts to combat resistant bacteria with engineered strainsClues to complexity
Study determines genetic variants of PTSDPreventing the next pandemic
Two leading scientists call on health agencies to invest in broadly effective vaccinesThree old mice, see how they run
USC’s ‘exercise protein’ doubles running capacity and extends healthy lifespans in older micePreclinical
Taking aim at Bcl-xL
Scientists identify a new target for treating age-related eye diseases
Q&A: Engineering the immune system
Engineering and nanotechnology turn immune cells into a cancer drug delivery system
Advances in Fabry disease
Amicus’ engineered hGLA showed greater substrate reduction than wildtype hGLA
Synthetic lethal drugs vs. cancer
Company obtains funding to advance precision oncologyEditor's Focus
COVID-19: Side effects and unintended benefits
The pandemic has not been good to us, but some good things might come out of itTeaming science while spreading risk—It’s a lottery that works
It takes real strength of character to accept the high risk in pharma and biotech and not be psychologically crippled by itCommentary
Real world evidence market is growing fast
Applications of RWE-based insights range from drug discovery to supporting regulatory decision-makingSpecial Reports
Special Report on Neuroscience: Demystifying psychedelics
Researchers add analysis to the mix to move beyond anecdotesFeature
